The prevalence of Diabetic Peripheral Neuropathy is 29–49% in people with Diabetes Mellitus, up to 50% of them develop Neuropathic Pain. The reasons for this are not completely understood and this heterogeneity cannot be always captured by a single molecular assay. Studying the molecular changes at the level of genetic variation; the gene and protein expression; the quantity of metabolites and serum biomarkers can reveal composite signatures explaining the heterogeneity of the disease. I will discuss how we can utilise multi-omics data integration and analysis to discover composite biomarkers associated with the presence and intensity of Neuropathic Pain